Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

114.74 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 318
Open 114.74
Bid (Size) 114.50 (1)
Ask (Size) 114.74 (1)
Prev. Close 114.74
Today's Range 114.74 - 114.74
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Covid Era Tech Promises To Reinvent Cancer Treatment
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
Exposures COVID-19
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct

Performance

YTD
+1.32%
+1.32%
1 Month
-1.58%
-1.58%
3 Month
-10.16%
-10.16%
6 Month
-11.98%
-11.98%
1 Year
+11.89%
+11.89%

More News

Read More
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
From Merck & Co., Inc.
Via Business Wire
Is Merck Stock a Buy?
Via The Motley Fool
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Merck & Co Unusual Options Activity For September 23
Via Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
Via The Motley Fool
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Via Benzinga
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
From Merck & Co., Inc.
Via Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Exploring NYSE:MRK's dividend characteristics.
Via Chartmill
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Via Benzinga
Exposures Product Safety
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Via Benzinga
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
From Merck & Co., Inc.
Via Business Wire
Pfizer Advances On Its Cancer Journey
Via Benzinga
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
From Merck & Co., Inc.
Via Business Wire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Via FinancialNewsMedia
Is It Too Late to Buy ServiceNow Stock?
Via The Motley Fool
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.